Kamada's third quarter split along a familiar line: the top line disappointed and profitability did not. The company earned $0.14 per share, beating the $0.13 consensus by 7.7% and growing earnings 55.6% year over year. Revenue of $52.03 million rose 10.7% but missed the $53.51 million consensus by 2.8%. More consequential than either figure, management raised full-year 2026 guidance for the first time after three straight reaffirmations. Revenue is now expected at $205 million to $208 million, up from $200 million to $205 million. Adjusted EBITDA is now expected at $52 million to $54 million, up from $50 million to $53 million. Management also projected double-digit revenue and profit growth for 2027. That is the central tension: a soft revenue print paired with a more confident outlook.

The revenue miss deserves context. Q3 sales were down sequentially from a record $54.9 million in Q2. That quarter grew 23% year over year, partly because shipments slipped out of Q1, so some normalization was predictable. Growth was also uneven by segment:

• **Proprietary products** rose about 12% to $44.2 million, led by KEDRAB in the U.S., VARIZIG and HEPAGAM.
• **Distribution** grew only about 5% in the quarter to $7.8 million, even though it is up 35% for the first nine months.

The earnings quality is better than the revenue line:

• **Gross margin** expanded to 45% from 42% a year ago, driven by a richer proprietary product and market mix.
• **Operating income** climbed to $10.4 million from $7.8 million.
• **Adjusted EBITDA** rose 30% to $15.2 million, a 29% margin, up from 26% in Q2.

Some of the bottom-line lift came from below and around the core business. A smaller revaluation charge on long-term liabilities helped, and nine-month R&D spending fell to $6.7 million from $10.1 million. Meanwhile, G&A and selling expenses are rising with commercial expansion.

Cash generation was the standout. Operating cash flow reached $19.9 million in Q3, nearly double the $10.4 million a year earlier. That figure was flattered by a $9.4 million reduction in receivables, while inventories rose $5.8 million. Even so, nine-month operating cash flow of $37.6 million versus $17.9 million shows profits converting to cash. Cash held flat at $75.3 million only because Kamada paid $24.2 million in dividends this year. It declared another $0.14 per share, bringing 2026 payouts to roughly $32 million.

The call sharpened the forward narrative. KEDRAB demand is benefiting from a CDC rabies health advisory, with partner Kedrion ordering well above its minimum commitments. Management expects the strength to persist into 2027 and says it has the inventory and capacity to meet it. Bears can fairly argue that advisory-driven demand may prove episodic.

Other developments add new revenue sources:

• **Biosimilars:** two more launched in Israel in Q3, and at least two more are planned for 2027. Management set a new trajectory of about $10 million in revenue in 2028 and $20 million to $25 million by 2030, above the earlier target of $15 million to $20 million within four to five years.
• **Plasma supply:** first normal source plasma sales under the three-year, roughly $50 million contract begin in Q4.

The raised guidance implies a strong finish. Based on reported nine-month results, it points to Q4 revenue of roughly $53 million to $56 million and adjusted EBITDA of about $11 million to $13 million. Both would be well above the prior-year fourth quarter.

Several risks remain:

• **Gross margin:** the nine-month rate of 43% still trails last year's 44%, and the vertical-integration benefit from owned plasma is not yet in the P&L.
• **M&A:** a deal has been promised since early in the year and remains unexecuted, though management hinted at good news in the near term.

The market had not been rewarding the story heading into the print. Shares were at $7.23 shortly before the report, only 2.0% above the open following the August release. They had given back most of a run to $8.96 in late September and sat just 6.8% above an inter-earnings low set on November 5. The stock was also 9.7% below its 200-day moving average. Investor sentiment was negative and essentially unchanged at about -0.43, so expectations were already subdued. Price and AVWAP trend readings remain negative even as momentum has turned positive.

The bottom line is that Kamada delivered a quarter where margin expansion, cash conversion and a guidance raise outweighed a modest revenue miss and a sequential dip. The raise, the 2027 growth projection and an upgraded biosimilar path improve the fundamental setup for a stock trading near the bottom of its recent range. Whether investors buy in likely depends on two things: whether KEDRAB strength proves durable beyond the CDC advisory, and whether management finally converts its M&A talk into a deal.